INTS on XNAS, Health Care, Intensity Therapeutics, Inc., job postings
Measures activity, not value. Not investment advice.
Shares fell 74% in a year while net loss reached $12M against $8.5M cash.
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Industry
Biological products, (no diagnostic substances) (Health Care)
expected around 4 Mar 2027 (an estimate: a year ago it reported on 5 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $3.5M.
30 Jun 2022RevenueNet incomeNet losstallest bar $5.0M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$3.5M
30 Jun 2026
–
-$3.0M
31 Mar 2026
–
-$2.4M
31 Dec 2025
–
-$3.1M
30 Sep 2025
–
-$2.7M
30 Jun 2025
–
-$2.5M
31 Mar 2025
–
-$3.3M
31 Dec 2024
–
-$3.2M
30 Sep 2024
–
-$3.5M
30 Jun 2024
–
-$5.0M
31 Mar 2024
–
-$4.6M
31 Dec 2023
–
-$3.2M
30 Sep 2023
–
-$2.3M
30 Jun 2023
–
-$3.7M
31 Mar 2023
–
-$1.3M
31 Dec 2022
–
-$1.5M
30 Sep 2022
–
-$1.8M
30 Jun 2022
–
-$1.9M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$12.0M
-$11.7M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-162%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$8.5M
$7.1M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$8.5M (net cash)
-$7.1M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$2.32
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
1.1
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
26%
874K shares held by 13F filers (30 Sep 2026) of 3.3M outstanding (4 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
2.3%
76K shares sold short (30 Oct 2026) of 3.3M outstanding (4 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
7.2
76K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-14%
88K shares sold short in the report before, 76K on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
29%
29% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 50%
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
6
6 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
6 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.
Price $2.48 on 20 Nov 2026, -74% over 12 months (12-month range $2.48 to $14.75)
Sharp change
8-K and other filings
Institutional holders (13F filers). 15 13F filers reported holding it in the latest 13F quarter, -40% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: insider net buying (open market), h-1b/e-3 applications certified, revenue per quarter, capital spending per quarter, federal obligations, lobbying spend, workers in warn layoff notices.
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is diluted earnings per share, fiscal year at -$8.6 (31 Dec 2025), 520% below its normal quarter of -$1.4; higher than 25% of its own history.
Changes and notable records, by the date each became public
25 Dec 2025Short interest and volume change
had 2.9M shares sold short in the 15 Dec 2025 report, 47× the same report last year.
Same report last year: 62K; its normal report is 321K.
See the evidence
This period
2.9M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
321K
Typical spread (median absolute deviation)
270K
How far from its usual level
+6.6
Same report last year
62K
History used
885 days
the 15 Dec 2025 report24 earlier reportsnormal: 321K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.5M shares sold short in the 28 Nov 2025 report, 65× the same report last year.
Same report last year: 39K; its normal report is 215K.
See the evidence
This period
2.5M (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
215K
Typical spread (median absolute deviation)
174K
How far from its usual level
+8.9
Same report last year
39K
History used
868 days
the 28 Nov 2025 report24 earlier reportsnormal: 215K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.6M shares sold short in the 14 Nov 2025 report, 83× the same report last year.
Same report last year: 43K; its normal report is 166K.
See the evidence
This period
3.6M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
166K
Typical spread (median absolute deviation)
126K
How far from its usual level
+18.3
Same report last year
43K
History used
854 days
the 14 Nov 2025 report24 earlier reportsnormal: 166K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 16.8M shares sold short in the 31 Oct 2025 report, 379× the same report last year.
Same report last year: 44K; its normal report is 110K.
See the evidence
This period
16.8M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
110K
Typical spread (median absolute deviation)
70K
How far from its usual level
+161.2
Same report last year
44K
History used
840 days
the 31 Oct 2025 report24 earlier reportsnormal: 110K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.3M shares sold short in the 15 Oct 2025 report, 55× the same report last year.
Same report last year: 41K; its normal report is 61K.
See the evidence
This period
2.3M (the 15 Oct 2025 report)
Normal report (median of 24 earlier)
61K
Typical spread (median absolute deviation)
22K
How far from its usual level
+43.9
Same report last year
41K
History used
824 days
the 15 Oct 2025 report24 earlier reportsnormal: 61K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 866K shares sold short in the 30 Sep 2025 report, 29× the same report last year.
Same report last year: 30K; its normal report is 58K.
See the evidence
This period
866K (the 30 Sep 2025 report)
Normal report (median of 24 earlier)
58K
Typical spread (median absolute deviation)
20K
How far from its usual level
+16.2
Same report last year
30K
History used
809 days
the 30 Sep 2025 report24 earlier reportsnormal: 58K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 671K shares sold short in the 29 Aug 2025 report, 30× the same report last year.
Same report last year: 22K; its normal report is 52K.
See the evidence
This period
671K (the 29 Aug 2025 report)
Normal report (median of 24 earlier)
52K
Typical spread (median absolute deviation)
14K
How far from its usual level
+12.4
Same report last year
22K
History used
777 days
the 29 Aug 2025 report24 earlier reportsnormal: 52K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 988K shares sold short in the 15 Aug 2025 report, 50× the same report last year.
Same report last year: 20K; its normal report is 52K.
See the evidence
This period
988K (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
52K
Typical spread (median absolute deviation)
13K
How far from its usual level
+18.7
Same report last year
20K
History used
763 days
the 15 Aug 2025 report24 earlier reportsnormal: 52K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 945K shares sold short in the 31 Jul 2025 report, 17× the same report last year.
Same report last year: 57K; its normal report is 52K.
See the evidence
This period
945K (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
52K
Typical spread (median absolute deviation)
12K
How far from its usual level
+17.9
Same report last year
57K
History used
748 days
the 31 Jul 2025 report24 earlier reportsnormal: 52K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 660K shares sold short in the 13 Jun 2025 report, 20× the same report last year.
Same report last year: 33K; its normal report is 44K.
See the evidence
This period
660K (the 13 Jun 2025 report)
Normal report (median of 24 earlier)
44K
Typical spread (median absolute deviation)
12K
How far from its usual level
+12.3
Same report last year
33K
History used
700 days
the 13 Jun 2025 report24 earlier reportsnormal: 44K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 44 entries; narrow the window or the kind of data to see older ones.
Not listed: 48 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001567264
Ticker
INTS
Domain
intensitytherapeutics.com
Hq location
CT|SHELTON|06484 (1 unverified)
Name
Intensity Therapeutics, Inc.
SEC Form 13F institutional holdings126 data points30 Jun 2023 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)79 records28 Oct 2021 to 5 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)217 data points31 Dec 2021 to 4 Nov 2026
FINRA short interest (twice monthly)239 data points14 Jul 2023 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)1706 data points30 Jun 2023 to 20 Nov 2026